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ABSTRACT 
International Journal of Exercise Science 9(5): 607-615, 2016. Smokers, and even non-
smokers, may utilize vaporized nicotine delivered by electronic cigarette (EC) due to the perception that EC 
are “healthier” than traditional tobacco cigarettes. The effects of vaporized nicotine delivered by EC on 
resting blood pressure (BP) and resting metabolic rate (RMR), or BP and aerobic power during exercise have 
not been studied. This investigation tested the effects of acute vaporized nicotine inhalation by EC on 
resting BP and RMR and cycle exercise BP, metabolic responses, and aerobic power in young, normotensive 
non-smokers. Using a double-blind design, 20 subjects (10 female) participated in two randomized trials: 
placebo (0 mg nicotine) or nicotine (18 mg nicotine). Participants inhaled from EC once every 30 s for 10 min 
(20 inhalations total). RMR was assessed 40 min later by indirect calorimetry followed by an incremental 
cycle test. RMR was not different between trials (p=0.79). Compared to the placebo, resting diastolic 
pressure (DBP) was 3 mmHg higher with nicotine (p=0.04). VO2peak was not different between the nicotine 
trial (2.3±0.8 L•min-1) and placebo (2.3±0.7 L•min-1) trials (p=0.77), and Wmax was also similar between 
nicotine (201.0±53.8 W) and the placebo (204.8±57.8 W) (p=0.29). During the cycle exercise test, average DBP 
was higher following nicotine use compared with placebo trial (p=0.05), and exercise DBPpeak after nicotine 
(79.4±7.6) was significantly higher than placebo (74.9±8.3 mmHg) (p=0.02). Resting systolic blood pressure 
(SBP) was 3.7 mmHg lower for nicotine trial (p=0.04) but no SBP treatment effect was observed during 
exercise (p=0.14). Our results show that acute vaporized nicotine inhalation via EC increases resting and 
exercise DBP but does not affect RMR or cycle aerobic power in young, normotensive non-smokers. 
 




Electronic cigarettes (EC) are nicotine delivery devices marketed as an over-the-counter 
alternative for smokers. Recent reviews suggest that EC may be effective in reducing tobacco-
related morbidity and mortality (8), and may represent a lower health risk option for smokers 
wishing to quit (1). These suggestions are based on reports showing that EC do not contain 
carbon monoxide and other harmful components associated with conventional tobacco 
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cigarettes. EC deliver vaporized nicotine from a propylene glycol or glycerol suspension 
heated with an inhalation-activated element. To date, research on EC has primarily focused on 
health risk reduction and smoking cessation efficacy (15, 19, 21, 27). However, the 
physiological effects of inhaling vaporized nicotine pertaining to metabolism and exercise 
performance have not been assessed. 
 
Nicotine increases resting metabolic rate (RMR) resulting in additional caloric expenditure 
(26). Because vaporized nicotine delivered by EC is marketed as “safer” than conventional 
smoking, the general public may perceive EC as a viable weight loss tool. Nicotine also 
stimulates the cardiopulmonary system (5), which, in turn, may increase the stress of 
performing physical activity (PA) (25). These interactions could make exercise for uses of EC 
problematic. Difficulty in performing PA and reduced physical capacity may decrease the 
ability of EC users to accumulate the desired daily prescription of PA for health, especially 
moderate-intensity PA (13). Therefore, EC users’ wellbeing could be affected by vaporized 
nicotine directly and indirectly by the co-morbidities associated with low capacity for PA.  
 
The purpose of this study was to test the hypotheses that acute use of vaporized nicotine 
delivered via EC would increase resting blood pressure (BP) and RMR, and increase exercise 
BP while decreasing aerobic power in young, normotensive non-smokers. The findings from 






Twenty (10 female) volunteer subjects self-reporting as healthy and non-smoking participated 
(age=23.1±2.5 years, height=1.69±0.1 m, weight=70.6±14.9 kg; all body fat=22.1±11.0%, male 
body fat=15.3±6.7%, female body fat=28.8.1±10.5%). Subjects were pre-screened for self-
reported abstinence from any tobacco products including EC within the past year, known 
cardiovascular, respiratory, or metabolic abnormalities, prescription or non-prescription drug 
use, and pregnancy (all female subjects underwent a urine pregnancy test to ensure they were 
not pregnant). Subjects’ resting seated blood pressure was ≤120 mmHg systolic (SBP) and ≤80 
mmHg diastolic (DBP). Participants signed a written consent form approved by the 
Institutional Review Board for Human Subject Research at the University of Texas at San 
Antonio prior to the commencement of any experimental procedures. Consenting subjects had 
their height and weight with minimal clothing measured prior to having body composition 
assessed via bioelectrical impedance (BIA; TBF-410, Tanita, Arlington Heights, IL). 
 
Protocol 
Subjects participated in two randomized trials separated by ≥1 week: placebo 0 mg•ml-1 
nicotine EC trial and 18 mg•ml-1 nicotine EC trial. Participants were asked to refrain from 
caffeine, alcohol, dietary supplements, medications, and any activity (e.g., exercise) above that 
required for basic grooming and activities of daily living for 12 h prior to both experimental 
sessions. Additionally, participants were instructed to eat an identical pre-trial evening meal 
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10 h prior (i.e., by 10 pm) to reporting to the laboratory (i.e., 8 am) with water intake 
encouraged until bedtime and sleep of at least 6 h (≥12 am) the nights before testing.  
 
Subjects reported to the laboratory at 8 am in the fasted condition and were instrumented with 
a heart rate (HR) monitor (Polar, Kempele, Finland) and automated sphygmomanometer 
(Omron Healthcare Inc., Lake Forest, IL) and then sat quietly for 10 min. Resting BP and HR 
were assessed before participants were provided a blinded EC and instructed to inhale deeply 
once every 30 s over the course of 10 min (20 inhalations total). Our inhalation procedure was 
chosen after informal observations of smokers’ average number of inhalations per traditional 
cigarette (unpublished observation based on 5 non-smoking pilot subjects, 2 female, of similar 
age and body composition). We instructed participants to inhale as deeply as possible 
although anecdotally, inhalation volume varied amongst subjects. During a 10 min quiet rest 
following use of the EC, participants completed a short questionnaire to assess subjective 
symptoms from the inhalations. At the conclusion of the 10 min rest period, participants 
provided a urine sample for the assessment of cotinine (NicAlert, Biosciences Inc, San Diego, 
CA). Seventy to eighty percent of inhaled nicotine is rapidly metabolized to cotinine and 
therefore this surrogate biomarker found in the blood and urine is commonly used to assess 
nicotine exposure levels (7). Post-nicotine exposure cotinine levels are much higher in urine 
than those found in blood (28). In a preliminary test of the EC inhalation protocol utilized in 
this study, ranges of urine cotinine concentrations during development of this protocol were 
significantly higher after nicotine (75±5 ng•ml-1) compared to placebo trials (5±1 ng•ml-1) 
using the same inhalation schedule. (n=4, p<0.001, unpublished observation) and this value is 
similar to that in non-smokers exposed to second-hand smoke (7). 
 
RMR was assessed by indirect calorimetry. Subjects were asked to lay supine while a 
lightweight see-through canopy was placed over their neck and head. Room air entered the 
canopy from a one-way port, while expired air was collected from another one-way port inline 
with a metabolic measurement system (ParvoMedics TrueMax 2400, Sandy, UT). To ensure 
metabolic rate was representative of resting levels, instrumented subjects lay motionless on an 
exam table with as little visual or auditory stimulation as possible for 15 min prior to the actual 
10-min data collection period. 
 
Expired air was analyzed to estimate whole-body oxygen consumption (VO2; L•min-1). Caloric 
energy expenditure (kcal•min-1) was then estimated using the thermal equivalents of oxygen 
for the non-protein respiratory quotient (RQ) (4). Average energy expenditure, VO2, RQ, HR, 
SBP, and DBP were made over the last 5 min of the 10-min indirect calorimetry period. It 
should be noted that these resting measurements were assessed starting ~40 min following the 
last EC inhalation (i.e., following 10 min of seated rest + 10 min for urine collection and 
instrumentation + 15 min of supine rest + 5 min of supine indirect calorimetry). Subjects then 
transitioned to a cycle ergometer for the exercise test.  
 
The incremental cycle test protocol commenced 5 min following RMR testing to evaluate 
participants’ peak power output and cardiorespiratory response and peak aerobic capacity. 
Subjects were instrumented with a facemask for indirect calorimetry. Subjects rested on a pre-
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fitted and calibrated electronically braked cycle ergometer (Lode Excalibur, Lode B.V., 
Groningen, The Netherlands) for 5 min prior to beginning exercise. Because all subjects were 
healthy, an incremental cycle VO2max protocol was used whereby workrate started at 15 W and 
increased by 15 W each minute. Subjects were instructed to maintain 60-70 RPM while pedal 
resistance changed according to the desired stage workrate. Subjects cycled until they could no 
longer maintain the RPM or pedal force to maintain the desired workrate. Whole-body VO2, 
HR, SBP, and DBP were assessed over the last 15 s of each stage. Indirect calorimetric 
estimations of energy utilization during exercise were assessed similar to that described for 
RMR above. Cycle exercise began ~55 min following the last EC inhalation (40 min of pre-
indirect calorimetry + 5 min of indirect calorimetry + 5 min of cycle instrumentation + 5 min of 
seated rest on cycle). 
 
Statistical Analysis 
Statistical analyses were performed with SigmaPlot (Systat Software Inc., San Jose, CA) Urine 
cotinine concentrations, RMR data, as well as cycle exercise VO2peak, and Wpeak were evaluated 
using a paired t-test. The cycle exercise response was also assessed using a two-way repeated 
measures analysis of variance (ANOVA) for intervention (nicotine vs. placebo) and time. Data 
for 45, 90, and 135 W were used for submaximal analyses, as all 20 participants completed 
these stages. In the event of significant interactions between groups, results were explored 
further with Bonferroni post-hoc tests. Data are presented as means ± standard deviation (SD) 




Participants’ pre-inhalation SBP, DBP, and HR were not significantly different between 
conditions or from those averaged over the last 5 min of the indirect calorimetry protocol 
(Table 1). 
 
Table 1. Supine resting conditions ~40 min following nicotine and placebo trial inhalations.  
 Nicotine trial n=20 Placebo trial n=20 
RMR (kcal•min-1) 1.18±0.2 1.19±0.2 
VO2 (L O2•min-1) 0.25±0.0 0.25±0.1 
RQ (arbitrary units) 0.78±0.1 0.79±0.01 
HR (b•min-1)      61±10.2 61±10.1 
SBP (mmHg) 112.1±6.8* 115.8±8.0 
DBP (mmHg) 76.6±6.0* 73.6±8.3 
Values are means ± SD. *p=0.04.  
 
A single brand of over-the-counter EC was used for this study (Green Smart Living, Salt Lake 
City, UT). The 18 mg and 0 mg EC cartridges are marketed to vary only in nicotine content. As 
described above, cotinine was assessed on post-inhalation (i.e., 10 min) urine samples. The 
cotinine concentration ranges, as scored using the semi-quantitative urine analysis kit strips, 
were significantly higher (p<0.001) after nicotine inhalation (30-100 ng•ml-1) compared to 
placebo (0-10 ng•ml-1).   
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RMR was assessed ~40 min after the last EC inhalation. RMR (p=0.39), VO2 (p=0.5), RQ 
(p=0.15), and HR (p=0.47) were not significantly different between the placebo and nicotine 
trials (Table 1). Compared to the placebo trial, nicotine use resulted in a 3.7 mmHg lower 
resting SBP (p=0.04) but a 3.0 mmHg higher DBP (p=0.04) (Table 1). 
 
VO2peak was not different between the nicotine trial (2.3±0.8 L•min-1) and placebo trial (2.3±0.7 
L•min-1) trials (p=0.77, Figure 1B). No statistically distinguishable difference was observed for 
Wpeak between nicotine (201.0±53.8 W) and placebo (204.8±57.8 W) (p=0.29, Figure 1B). There 
was a main effect of time over the cycle test for VO2 (Figure 1A), energy expenditure, RQ, and 
HR but no between treatment effects. 
 
 
Figure 1. Submaximal VO2 versus power output (A) with (B) VO2peak and Wpeak results from incremental cycle 
test. Trial means ± SEM. 
 
A main treatment effect was identified for DBP, which was higher following nicotine 
compared to placebo at all time points during the test (p=0.05, Figure 2A). No time by 
treatment interaction was identified for any variable during exercise. Exercise DBPpeak after 
nicotine (79.4±7.6) was significantly higher (p=0.02) than placebo (74.9±8.3 mmHg) (Figure 2B). 




The potential of EC use on smoking cessation efficacy and possible health risk reduction 
compared to traditional cigarettes has been evaluated (15, 19, 21, 27). However, to our 
knowledge the physiological effects of vaporized nicotine inhalation on energy metabolism 
and exercise performance have not been addressed. In this study, we report the acute 
cardiorespiratory and performance effects of vaporized nicotine delivered via EC at rest and 
during cycle exercise in young, normotensive non-smoking subjects. 
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Figure 2. Submaximal DBP versus power output (A) with (B) DBPpeak results from incremental cycle test. Trial 
means ± SEM. 
 
 We hypothesized that acute EC (18 mg nicotine) use would result in elevated resting caloric 
expenditure. However, no differences were observed for RMR or other cardiorespiratory 
measures between nicotine and placebo trials aside from those found for DBP. Perkins et al. 
(26) identified a slight placebo effect on RMR from inhalation of a placebo (zero nicotine 
content) cigarettes. This finding indicates possible physical and/or behavioral but non-
pharmacological aspects of smoking that may also contribute to acute increases in RMR with 
the act of smoking. Our protocol did not include a “non-smoking” arm, so it was not designed 
to ascertain this putative effect with inhalation on a placebo EC. From the present findings, the 
potential for acute EC to alter metabolism is not apparent, and the long-term metabolic effects 
of EC use need to be investigated. 
 
Perkins et al. (25) detected a two-fold greater steady-state energy expenditure attributable to 
nicotine use compared to placebo in smokers. This effect was not observed following EC use in 
non-smokers during our incremental protocol. This may be attributable to different responses 
in non-smokers versus smokers with acute and single exposure. 
 
Nicotine delivered by traditional cigarettes is known to acutely increase arterial pressure and 
HR via elevated sympathetic activity (9, 11, 18, 22, 23) and impaired cardiac diastolic function 
in smokers (3) and non-smokers (2). Farsalinos et al. (2014) recently reported a statistically 
significant 3 mmHg greater DBP 5-min following acute EC use (11 mg•ml-1) in chronic EC-
using ex-smokers. We also found a 3 mmHg higher DBP ~40 min following nicotine 
inhalations in young, normotensive non-smokers in itself does not necessarily indicate a 
clinically relevant finding.  
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DBP was also significantly higher during the nicotine trial at all submaximal exercise 
intensities compared with the placebo condition. Additionally, exercise DBP at VO2peak 
following nicotine inhalation was 4.5 mmHg higher than placebo. We recently reported higher 
resting and orthostatic arterial pressures in young, normotensive non-smokers following acute 
EC nicotine exposure compared with placebo (10), and suggest that this and our current 
observations are related to known increases in plasma catecholamines observed with smoking 
(16). A slightly higher DBP observed at rest and during exercise warrants further investigation. 
If acute exposure to vaporized nicotine raises DBP in normotensives, a commensurate increase 
in exercising hypertensive individuals could hold clinical significance with respect to 
cardiovascular disease risk. Whether resting and/or exercise differences would be observed 
with EC use in smokers, hypertensive, older, and cardiac diseased individuals remains to be 
explored. 
 
Our findings are not without methodological limitations. First, the actual nicotine level in 
commercially available EC may vary from advertised concentrations (17, 19) and affect total 
and between-subject variability of nicotine dosage. Secondly, the volume of vapor inhaled by 
our subjects was not controlled and may have varied across individuals and across trials. 
Anecdotally, observed inhalations were shallow in most subjects making possible comparisons 
with estimated lung volume and subsequent cotinine levels dubious. The new and 
uncomfortable feel of the vapor occasionally made subjects cough and sneeze in some 
instances, but not consistently. The ~40 min period between inhalations and RMR as well as 
the 55 min post-inhalation period before exercise could have affected possible trial differences 
if the effects of nicotine had waned or not reached maximal effectiveness. Finally, our cotinine 
test kit only provided wide ranges for values. This, and the questionable reliability of the 
values that we did measure made statistical analyses and other comparisons equally 
unreliable. 
 
Epidemiological studies confirm that electronic cigarette use is expanding worldwide (14, 20, 
6) with growing popularity among adolescents (12, 20) and non-smokers (24). Perception of EC 
as a safe and viable weight loss tool or recreational stimulant warrants public awareness of 
any concomitant negative physiological effects. Nicotine has been shown to elevate whole-
body energy metabolism (26) and stress the cardiopulmonary system (5), both of which could 
make physical activity for smokers problematic. The mild increase in DBP at rest and during 
exercise warrants continued assessment of the cardiovascular and metabolic effects of chronic 
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